Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Alyssa, Birt"'
Autor:
Yanping Yang, Huan Yang, Yago Alcaina, Janusz Puc, Alyssa Birt, Yogindra Vedvyas, Michael Gallagher, Srinija Alla, Maria Cristina Riascos, Jaclyn E. McCloskey, Karrie Du, Juan Gonzalez-Valdivieso, Irene M. Min, Elisa de Stanchina, Matt Britz, Eric von Hofe, Moonsoo M. Jin
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-13 (2023)
Abstract The limited number of targetable tumor-specific antigens and the immunosuppressive nature of the microenvironment within solid malignancies represent major barriers to the success of chimeric antigen receptor (CAR)-T cell therapies. Here, us
Externí odkaz:
https://doaj.org/article/1773c1a113ad431dbfb194f4da0fc107
Autor:
Christine Ambrose, Lihe Su, Lan Wu, Fay J Dufort, Thomas Sanford, Alyssa Birt, Benjamin J Hackel, Andreas Hombach, Hinrich Abken, Roy R Lobb, Paul D Rennert
Publikováno v:
PLoS ONE, Vol 16, Iss 3, p e0247701 (2021)
Successful CAR T cell therapy for the treatment of solid tumors requires exemplary CAR T cell expansion, persistence and fitness, and the ability to target tumor antigens safely. Here we address this constellation of critical attributes for successfu
Externí odkaz:
https://doaj.org/article/79b29881299c40a5997a27b51c18789e
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/29ca25875ed04214bdf8dfc827f09f7d
Autor:
Roy R. Lobb, Lan Wu, Christine Ambrose, Lihe Su, Paul Rennert, Thomas J Sanford, Fay J. Dufort, Alyssa Birt
Publikováno v:
Molecular Cancer Therapeutics. 20:2071-2081
Refractory acute myeloid leukemia (AML) remains an incurable malignancy despite the clinical use of novel targeted therapies, new antibody-based therapies, and cellular therapeutics. Here, we describe the preclinical development of a novel cell thera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f5022f2671ddd6c6418c5a00c36673b
https://doi.org/10.1158/1535-7163.mct-20-1030
https://doi.org/10.1158/1535-7163.mct-20-1030
Autor:
Justin R. Klesmith, Roy R. Lobb, Alyssa Birt, Benjamin J. Hackel, Ian A. Schrack, Paul Rennert, Lan Wu, Christine Ambrose, Lihe Su, Fay J. Dufort
Publikováno v:
Molecular Pharmaceutics. 16:3544-3558
CD19-targeted chimeric antigen receptor (CAR) T-cells (CAR19s) show remarkable efficacy in the treatment of relapsed/refractory acute lymphocytic leukemia and Non-Hodgkin's lymphoma. However, the use of CAR T-cell therapy against CD19-negative hemato
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db618f8499ca295995e1460dbc3b2e71
https://doi.org/10.1021/acs.molpharmaceut.9b00418
https://doi.org/10.1021/acs.molpharmaceut.9b00418
Autor:
Yanping Yang, Huan Yang, Yago Alcaina, Jaclyn E. McCloskey, Janusz Puc, Alyssa Birt, Yogindra Vedvyas, Juan Gonzalez-Valdivieso, Irene M. Min, Eric von Hofe, Moonsoo M. Jin
Publikováno v:
Cancer Research. 82:5568-5568
Introduction: The application of chimeric antigen receptor (CAR) T cells in solid tumors has met many challenges, arising from the paucity of effective yet safe targets and T cell dysfunction within the immunosuppressive milieu. Clinical trials over
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5dff0ac8dcfaf68911be8369060fd9f7
https://doi.org/10.1158/1538-7445.am2022-5568
https://doi.org/10.1158/1538-7445.am2022-5568
Autor:
Roy R. Lobb, Andreas Hombach, Hinrich Abken, Lan Wu, Alyssa Birt, Christine Ambrose, Lihe Su, Benjamin J. Hackel, Paul Rennert, Fay J. Dufort, Thomas J Sanford
Publikováno v:
PLoS ONE, Vol 16, Iss 3, p e0247701 (2021)
PLoS ONE
PLoS ONE
Successful CAR T cell therapy for the treatment of solid tumors requires exemplary CAR T cell expansion, persistence and fitness, and the ability to target tumor antigens safely. Here we address this constellation of critical attributes for successfu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0011fdf32a5a97cec62e959975fa4028
https://doi.org/10.1101/2020.03.25.007658
https://doi.org/10.1101/2020.03.25.007658
Autor:
Jamie Maziarz, Manasi M. Kamat, Koryu Kin, Alyssa Birt, Troy L. Ott, Arun R. Chavan, Sreelakshmi Vasudevan, Mihaela Pavlicev, Deena Emera, Vincent J. Lynch, Günter P. Wagner
Publikováno v:
Genome Biology and Evolution
The endometrial stromal fibroblast (ESF) is a cell type present in the uterine lining of therian mammals. In the stem lineage of eutherian mammals, ESF acquired the ability to differentiate into decidual cells in order to allow embryo implantation. W
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab26aa450f431c52907a24bb68954126
https://doi.org/10.1093/gbe/evw168
https://doi.org/10.1093/gbe/evw168
Autor:
Fay J. Dufort, Alyssa Birt, Christine Ambrose, Lihe Su, Roy R. Lobb, Lan Wu, Paul Rennert, Thomas J Sanford
Publikováno v:
Molecular Cancer Therapeutics. 18:B020-B020
Introduction: Clinical data from diverse cell therapy trials highlight two critical issues. The first is resistance to, and relapse from, therapy due to antigen loss. In solid tumors antigen heterogeneity is common and cell therapies targeting a sing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1210662e0cb54129553d039867d010f3
https://doi.org/10.1158/1535-7163.targ-19-b020
https://doi.org/10.1158/1535-7163.targ-19-b020
Autor:
Roy R. Lobb, Lan Wu, Thomas J Sanford, Paul Rennert, Christine Ambrose, Lihe Su, Fay J. Dufort, Alyssa Birt
Publikováno v:
Blood. 134:252-252
Introduction CAR T cells that recognize the antigen CD19 (CAR19s) have achieved remarkable success in otherwise untreatable B cell malignancies including refractory and relapsed ALL and NHL. However, clinical data from diverse CAR19 trials, and real-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e5a6f978b073a2a240fccbf1d8ea63c
https://doi.org/10.1182/blood-2019-130654
https://doi.org/10.1182/blood-2019-130654